Bolt Biotherapeutics (BOLT) Expected to Post Earnings on Wednesday

Bolt Biotherapeutics (NASDAQ:BOLT) is expected to announce its Q3 2026 resultson Wednesday, November 11th. Analysts expect Bolt Biotherapeutics to announce earnings of ($3.6850) per share and revenue of $0.45 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Tuesday, August 11th. The company reported ($4.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.18). Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.50 million.

Bolt Biotherapeutics Trading Up 3.3%

Shares of BOLT opened at $6.45 on Wednesday. Bolt Biotherapeutics has a twelve month low of $3.10 and a twelve month high of $7.78. The stock has a market cap of $12.44 million, a PE ratio of -0.39 and a beta of 0.85. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 1.47. The business’s 50-day moving average price is $4.25 and its 200-day moving average price is $4.52.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $14.50.

Insider Transactions at Bolt Biotherapeutics

In related news, CEO William Quinn sold 9,132 shares of Bolt Biotherapeutics stock in a transaction on Friday, September 18th. The stock was sold at an average price of $3.24, for a total transaction of $29,587.68. Following the completion of the sale, the chief executive officer owned 25,384 shares of the company’s stock, valued at approximately $82,244.16. This trade represents a 26.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 38,584 shares of company stock worth $128,361 over the last three months. 9.40% of the stock is currently owned by company insiders.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment.

Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response.